GlassScriptPhysician profile
Srinivasan Vijayakumar
NPI 1184607210
$4,660.05
in general payments reported to CMS, 2019-2025
14 companies · $534 in 2025
The $534 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $62.43 · 2022: $3,074 · 2023: $132 · 2024: $15.41 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reflexion Medical, INC. | $2,398.97 | 2022 | |
| Elekta, INC. | $647.72 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $472.22 | 2022 | |
| United Imaging Healthcare North America, INC. | $285.00 | 2025 | N/A |
| Accuray Incorporated | $202.98 | 2022 | |
| Telix Pharmaceuticals | $133.61 | 2025 | Illuccix |
| Siemens Medical Solutions USA, INC. | $129.45 | 2023-2025 | Symbia Pro.Specta X7, Varian Ethos Treatment Planning |
| Blue Earth Diagnostics | $117.71 | 2023 | |
| Carl Zeiss Meditec, INC. | $112.63 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.73 | 2019 | |
| Novocure INC. | $46.84 | 2020 | |
| Pfizer INC. | $29.89 | 2019-2024 | |
| Incyte Corporation | $15.59 | 2020 | |
| Amgen INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivasan Vijayakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.